Compounded GLP-1 in 2026: What's Still Legal Now That the Shortage Is Over

When did the semaglutide and tirzepatide shortages officially end?

FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025, per FDA's compounder guidance. Both dates closed out messy paths: the tirzepatide determination followed an October 2, 2024 finding that litigation forced FDA to reevaluate before the final call landed two and a half months later.

A shortage listing is not a formality inside compounding law. While a drug sits on FDA's shortage list, 503A pharmacies and 503B outsourcing facilities can copy an FDA-approved drug's active ingredient without the usual compounding limits — the exact mechanism that let semaglutide and tirzepatide compounding scale into a mass-market telehealth business. Once FDA lifts that designation, the allowance starts winding down on a fixed clock, a process the compounded semaglutide crackdown traces in more detail.

What did the end of the shortage change for 503A and 503B compounders?

The end of the shortage did not make compounded semaglutide illegal outright — it removed the blanket exception. FDA's enforcement-discretion wind-down closed for tirzepatide on February 18, 2025 for 503A pharmacies and physicians and March 19, 2025 for 503B outsourcing facilities; for semaglutide the dates were April 22 and May 22, 2025. All four windows have now lapsed, and FDA states that neither drug 'currently appears on the 503B bulks list or on FDA's drug shortage list.'

Compounders challenged the shortage determinations in court and lost at every early stage. A federal district court denied the plaintiffs' preliminary-injunction motion on tirzepatide on March 5, 2025, and denied the parallel motion on semaglutide on April 24, 2025, in the Outsourcing Facilities Association's suits against FDA. Telehealth marketing often implies the legal fight remains wide open; the actual scoreboard so far runs against the compounders.

The fight is not over, though calling it settled misstates the record too. The semaglutide half of the case is now on appeal as Outsourcing Facilities Association v. FDA before the Fifth Circuit, with Novo Nordisk intervening on FDA's side and the federal government's brief filed in early 2026 — meaning the shortage-delisting question stays live, just not currently winning for compounders.

What does 'essentially a copy' mean in compounding law?

'Essentially a copy' decides whether a compounded drug needs its own FDA approval or can ride an existing one's coattails. Under 21 U.S.C. 353a(b)(2), a 503A pharmacy avoids the copy label only by changing the drug for a specific patient in a way that produces 'a significant difference, as determined by the prescribing practitioner'; the 503B version at 353b(d)(2)(B) requires 'a clinical difference' instead. Neither clause blesses a standing dose menu offered to anyone who fills out an intake form — the theory personalized-dosing GLP-1 programs actually rest on.

FDA spelled out its working test in an April 1, 2026 update. It treats a compounded product as essentially a copy if it shares the approved drug's active ingredient at 'the same, similar or an easily substitutable strength' by the same route, absent a documented prescriber finding of significant difference. Semaglutide combined with vitamin B12 counts as a copy once both ingredients land within 10% of approved strengths. FDA also said it does not intend to act against a compounder filling four or fewer prescriptions of a given product per calendar month.

What is FDA proposing for the 503B bulks list in 2026?

FDA is proposing, not finalizing, a rule that would exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list entirely. The April 30, 2026 announcement cites no clinical need for compounded versions now that branded supply has stabilized; Commissioner Marty Makary said 'when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.' The comment period closed June 29, 2026, and FDA says it will weigh those comments before any final determination, so the rule is not yet in effect.

Retatrutide and cagrilintide sit outside that debate because they were never eligible to begin with. FDA states flatly that both 'cannot be used in compounding under federal law' since neither is a component of an FDA-approved drug nor found safe and effective for any use, and it has warned telehealth sellers, API distributors and outsourcing facilities that touch either molecule. The same no-lawful-basis finding covers semaglutide salt forms such as semaglutide sodium and semaglutide acetate, which FDA treats as different active ingredients from the approved drugs.

Which telehealth GLP-1 models remain lawful today?

Three narrow lanes remain, and none of them resembles the mass-market compounding boom of 2022-2024. Prescriber-documented personalized dosing survives where a practitioner records, patient by patient, why the standard approved dose does not fit; low-volume compounding survives under FDA's stated four-prescriptions-a-month comfort zone; and plain telehealth prescribing of the branded drug — Ozempic, Wegovy, Mounjaro, Zepbound — was never touched by any of this, because no compounding happens at all.

Everything else runs on borrowed time or a false premise. GLP-1 microdosing offers marketed as a lighter-touch, lower-dose alternative sit inside the same essentially-a-copy analysis as full-dose compounding, not outside it — a lower dose alone does not exempt a product unless a prescriber documents why it is clinically warranted for that specific patient.

How many warning letters have GLP-1 compounders received since 2025?

The precise cumulative count needs checking against FDA's letter database, but the run rate is easy to document: more than 80 warning letters targeted GLP-1 or GLP-1-adjacent marketing between September 2025 and March 2026 alone. FDA itself said the volume of misleading-ad warnings it sent in the six months before March 2026 exceeded 'what had been sent over the entire preceding decade.'

Separately, FDA's adverse-event count offers a rough scale of harm reports rather than enforcement volume: as of May 31, 2026, the agency had logged 990 reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. FDA cautions these figures likely undercount the real total, because state-licensed 503A pharmacies face no federal mandate to report adverse events at all.

What are state boards doing about med-spa GLP-1 programs?

State medical boards are moving faster than federal rulemaking, and Alabama is the clearest example on record. Its Board of Medical Examiners stated in a May 2026 notice that 'under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient,' extended that bar to nurse practitioners and physician assistants, and rejected the idea that a 'research-grade' consent form limits liability.

State attorneys general are backing that stance with lawsuits, not just guidance. Alabama's AG sued Aurora IV and Wellness in November 2025 for injecting patients with lab-only-labeled tirzepatide and semaglutide while advertising it as pharmaceutical-grade; a January 2026 settlement forced the clinic to close permanently, pay roughly $24,000 and surrender a nursing license. Connecticut's AG extracted an $18,500 payment on a $300,000 suspended judgment from a raw-powder distributor in 2025, then moved in December 2025 to send cease-and-desist letters to three weight-loss businesses on corporate-practice-of-medicine grounds.

Ownership structure is now its own enforcement front. Oregon's SB 951, signed June 9, 2025, bars management services organizations from majority ownership or de facto clinical control over medical practices, phasing in from January 2026 for new arrangements and 2029 for existing ones. California's SB 351, effective January 1, 2026, bars private-equity and hedge-fund managers of physician practices from controlling clinical decisions, enforced by the state attorney general with no private right of action for individuals.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Nutra niche intelligence directory, Longevity and NAD+ Offers: Market Structure and Regulatory Status, Coffee, Tea and Powder Weight Offers: Format as the Angle, Gut Health and Microbiome Offers: Market Map and Rules, The Weight Loss Niche After GLP-1: What Still Sells and What Rules Apply, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.